MAT Niche Grafting: Impact on NMSC Healing & Scarring

May, 05, 2024 | Skin Cancer

KEY TAKEAWAYS

  • The objective was to evaluate the potential of employing 3D-printed MAT niche grafts in managing skin defects after NMSC resections.
  • The study demonstrated the viability of investigating the impacts of MAT niche grafting post-NMSC excision on healing and scarring.

Micronized adipose tissue (MAT) grafts have recently displayed encouraging outcomes in wound healing, including diabetic ulcers and non-melanoma skin cancer (NMSC).

Yu-Kyeong Yun and the team aimed to evaluate the potential for utilizing 3D-printed MAT niche grafts to manage defects from NMSC resections.

This retrospective study involved patients with skin and soft tissue defects due to NMSC resections. About 21 patients received treatment with either artificial dermis (n=11) or MAT niche (n=10) grafts. Healing time and POSAS scores were assessed for comparison. Statistical analysis utilized the Mann-Whitney U test and the Pearson chi-square test to compare both between and within groups based on preoperative and postoperative measurements.

The results revealed that wounds in the MAT niche group reepithelialized significantly faster than those in the artificial dermis group (mean [SD] 39.2 [11.4] days vs 63.7 [34.8] days; P=.04). In the evaluation of 21 scar parameters, individuals in the MAT niche group showed significantly superior outcomes in only 2 parameters based on operator assessment scores: relief (mean [SD] 1.6 [0.7] vs 2.2 [0.6]; P = .047) and scar contracture (mean [SD] 1.3 [0.5] vs 2.5 [1.0]; P = .011).

The study concluded that exploring the effects of MAT niche grafting post-NMSC excision on healing time and scarring parameters is feasible.

No funding-related information was available.

Source: https://pubmed.ncbi.nlm.nih.gov/38743859/

Yun YK, Han SK, Yoon IJ, et al. (2024). “Evaluating micronized adipose tissue niche and artificial dermis grafts following nonmelanoma skin cancer excision: a pilot study.” Wounds. 2024 Apr;36(4):129-136. PMID: 38743859.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –

Advertisement

LATEST

Advertisement

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy